#Canada #Toronto #AmacaThera #Merck Animal Health #hydrogel technology

AmacaThera and Merck Animal Health's Partnership

In an exciting development within the biotechnology sector, AmacaThera, known for its pioneering drug delivery solutions, has entered into a collaboration with the prestigious Merck Animal Health. This partnership aims to explore the potential of long-acting formulations that could significantly transform the landscape of veterinary care.

On May 1, 2025, AmacaThera made the announcement regarding this binding evaluation and option agreement, which is set to leverage the company’s innovative hydrogel technology, AmacaGel™. This platform represents a significant advancement in drug delivery, allowing for a sustained and effective release of therapeutic agents through a single injection. According to AmacaThera’s CEO, Mike Cooke, this collaboration brings together two industry leaders that share a commitment to enhancing animal health and welfare. He expressed his enthusiasm, stating, "We are thrilled to be collaborating with Merck Animal Health, a global leader in animal health. Together, we see immense value in leveraging each other's expertise to explore new frontiers in animal health."

AmacaGel™ is distinct due to its ability to enhance the sustained delivery of medications, which can potentially revolutionize care in veterinary medicine. This technology transforms into a depot upon injection, which could lead to improved outcomes for patients with chronic conditions or those requiring long-term therapy. The innovative hydrogel is designed to provide a wide compatibility with various drug modalities, which is a crucial factor in addressing current challenges faced in injectable drug delivery.

Merck Animal Health, a global brand recognized for its comprehensive range of animal healthcare products and innovative solutions, is equally enthusiastic about this collaboration. Chad Brown, Ph.D., who serves as the Global Head of Pharmaceutical Sciences and Clinical Supply at Merck, emphasized the value they see in merging their extensive expertise with AmacaThera's leading technology. Brown articulated their aspirations by saying, "We look forward to collaborating with AmacaThera as we continue to broaden our existing product portfolio of veterinary medicines and technology solutions."

Both companies aim to utilize their combined knowledge to expedite the development of products that address existing gaps in veterinary medicine, fulfilling critical unmet needs. Cooke highlighted the importance of AmacaThera's manufacturing capabilities, stating that their hydrogel platform not only promises rapid development of solutions but does so efficiently and cost-effectively. The potential of AmacaGel™ could change the way veterinary medicine approaches treatment—potentially improving the quality of life for animals everywhere.

About AmacaThera

AmacaThera is more than just a clinical-stage biotechnology firm; it is at the forefront of addressing essential challenges in therapeutic drug delivery. The company is dedicated to revolutionizing the field of medicine through advanced sustained-release hydrogel formulations. The flagship product, AMT-143, is currently advancing to Phase 2 clinical trials, showcasing great potential to be an effective alternative in post-operative pain management, specifically targeting the growing issue of opioid dependence.

About Merck Animal Health

Merck Animal Health, backed by a century of research and development, is committed to the advancement of animal welfare through a scientific approach. They offer a comprehensive suite of pharmaceuticals and health management solutions that extend to a global market. Their commitment to The Science of Healthier Animals® underscores a dedication to enhancing the health and welfare of animals, thus providing benefits to those who care for them.

In conclusion, the alliance between AmacaThera and Merck Animal Health signifies a promising advancement in veterinary medicine, aiming to enhance the efficacy of treatments and improve outcomes for animals worldwide. Together, these companies are poised to create substantial innovation in animal health solutions.